Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy

British Journal of Haematology
Jan WalewskiBastian von Tresckow

Abstract

Some patients with relapsed/refractory Hodgkin lymphoma (HL) are not considered suitable for stem cell transplant (SCT) and have a poor prognosis. This phase IV study (NCT01990534) evaluated brentuximab vedotin (1·8 mg/kg intravenously once every 3 weeks) in 60 patients (aged ≥18 years) with CD30-positive relapsed/refractory HL, a history of ≥1 prior systemic chemotherapy regimen, who were considered unsuitable for SCT/multi-agent chemotherapy. Primary endpoint was overall response rate (ORR) per independent review facility (IRF). Secondary endpoints included duration of response (DOR), progression-free survival (PFS) per IRF, overall survival (OS), proportion proceeding to SCT and safety. The ORR was 50%, with 12% CR; 47% proceeded to SCT. Median DOR was 4·6 months and median duration of CR was 6·1 months. After a median follow-up of 6·9 and 16·6 months, median PFS and OS were 4·8 months (95% confidence interval, 3·0-5·3) and not reached, respectively; estimated OS rate was 86% at 12 months. Most common adverse events (≥10%) were peripheral neuropathy (35%), pyrexia (18%), diarrhoea and neutropenia (each 10%). Brentuximab vedotin showed notable activity with a safety profile consistent with known toxicities, and may act as a b...Continue Reading

References

Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 12, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N L BartlettUNKNOWN Cancer Leukemia Group B
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Nov 15, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michelle A FanaleNancy L Bartlett
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Jul 24, 2013·Journal of the National Cancer Institute·Scarlett Lin GomezBarry A Miller
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D A EichenauerUNKNOWN ESMO Guidelines Working Group
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Dec 11, 2014·Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti·H MócikováD Belada
Aug 11, 2015·Annals of Internal Medicine·Wendy P BattistiYvonne E Yarker
Nov 7, 2015·Mayo Clinic Proceedings·Stephen M Ansell
Apr 26, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert ChenUNKNOWN KEYNOTE-087

❮ Previous
Next ❯

Citations

Feb 16, 2019·British Journal of Haematology·Alessandra RomanoFrancesco Di Raimondo
Aug 1, 2019·Cancers·Theodoros P VassilakopoulosKostas Konstantopoulos
Feb 29, 2020·Therapeutic Advances in Hematology·Theodoros P VassilakopoulosMaria K Angelopoulou
Jan 18, 2022·Leukemia & Lymphoma·Karan Chohan, Stephen M Ansell

❮ Previous
Next ❯

Related Concepts